Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential ...

Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research ...

Eli Lilly has announced positive topline results from the Phase III BRUIN CLL-313 trial of Jaypirca (pirtobrutinib), sending ...

Reversible BTK inhibitor Jaypirca (pirtobrutinib) has been shown in the BRUIN CLL-313 to significantly improve ...

Eli Lilly's approved blood cancer therapy Jaypirca helped delay progression of the disease in previously untreated patients ...

This strategic shift appears to be paying substantial dividends. While the broader pharmaceutical sector posted a 5.5% gain over the past month, Eli Lilly's shares surged by an impressive 16%. Market ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant ...

Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 ...

By nailing the primary endpoint in a phase 3 trial, Eli Lilly's Bruton tyrosine kinase (BTK) inhibitor Jaypirca has come one ...

Tesla’s share of U.S. EVE market drops below 40%. UnitedHealth reaffirms outlook. Goldman sees global music revenues doubling ...

Eli Lilly ( NYSE: LLY) said on Monday that its late-stage trial testing Jaypirca (pirtobrutinib), compared with chemoimmunotherapy, in patients with chronic lymphocytic leukemia or small lymphocytic ...